News
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product...
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ("FDA") Approval of D-PLEX .The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial;...
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate...
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline...
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors...
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions...
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and...
PolyPid to Participate in The Citizens Life Sciences Conference
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in a fireside chat at...
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections
Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company's...
PolyPid to Participate in the 37th Annual ROTH Conference
PETACH TIKVA, Israel, March 03, 2025 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will present at the 37th Annual ROTH Conference taking...